EMG measurement is feasible in primary care for stable mild to moderate COPD patients
This randomized controlled trial evaluated the feasibility and clinical application of parasternal electromyography (EMG) in patients with chronic obstructive pulmonary disease (COPD). The study population consisted of 40 participants with stable mild to moderate COPD (FEV1 ≥50% predicted) who were already using inhaled corticosteroid therapy. Recruitment occurred across 20 general practices in a primary care setting. Participants were followed for 6 weeks, with measurements taken at baseline, 3 months, and 6 months. The intervention involved the withdrawal of inhaled corticosteroid therapy over 6 weeks, compared to a maintenance group continuing therapy.
High-quality EMG data were successfully obtained from 35 of the 40 participants at baseline and from 31 participants on all three occasions. Intra-rater and inter-rater agreement for EMG measurements was high, with an intraclass correlation coefficient greater than 0.9. Lung function remained stable across the three time points, indicating a consistent study population. Safety and tolerability were not reported, and no adverse events, discontinuations, or serious adverse events were documented in the provided data.
Correlation analyses revealed a moderate negative correlation (r=-0.42, p=0.01) between resting EMG and FEV1% predicted. However, no correlation was observed between resting EMG and participant-reported breathlessness or health-related quality of life (HRQoL) measures. The study limitations include a small sample size and the lack of reported safety data or funding information. The authors note that while an association exists between EMG and airflow obstruction, no causation is implied, and the clinical utility of EMG in stable mild to moderate COPD remains uncertain.